Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046945 | 0.84 | PTGS2 (0.57) | PTGS2KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL499116 | 0.82 | GAA (0.61) | PTGS2KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL4965033 | 0.82 | PTGS2 (0.55) | PTGS2KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL2307800 | 0.82 | PTGS2 (0.55) | PTGS2KDM4EHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL4002124 | 0.81 | GAA (0.59) | PTGS2KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL7131019 | 0.81 | KMT2A (0.58) | PTGS2KDM4EALDH1A1MAPK1KMT2A | |
| SCHEMBL1991744 | 0.81 | PTGS2 (0.53) | PTGS2KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL2272890 | 0.81 | PTGS2 (0.53) | PTGS2KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL192064 | 0.81 | PTGS2 (0.53) | PTGS2KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL4683243 | 0.81 | KDM4E (0.55) | PTGS2KDM4EHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638546-B1 | Imidazolyl derivatives | IPSEN PHARMA S.A.S. (FR) | 2009-12-29 | — | — | US | disclosed |
| US-7566734-B2 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070299073-A1 | Imidazolyl derivatives | IPSEN PHARMA S.A.S. (FR) | 2007-12-27 | — | — | US | disclosed |
| US-7238695-B2 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2007-07-03 | — | — | US | disclosed |
| EP-1305294-B1 | IMIDAZOLYL DERIVATIVES | SOD CONSEILS RECH APPLIC (FR) | 2007-04-25 | — | — | EP | disclosed |
| EP-1086086-B1 | IMIDAZOLYL DERIVATIVES AND THEIR USE AS SOMATOSTATIN RECEPTOR LIGANDS | CONSEILS DE RECH SET D APPLIC (FR) | 2004-10-13 | — | — | EP | disclosed |
| US-20040176379-A1 | Imidazolyl derivatives | IPSEN PHARMA S.A.S. (FR) | 2004-09-09 | — | — | US | disclosed |
| EP-1086086-A1 | IMIDAZOLYL DERIVATIVES AND THEIR USE AS SOMATOSTATIN RECEPTOR LIGANDS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064401-A2 | IMIDAZOLYL DERIVATIVES AND THEIR USE AS SOMATOSTATIN RECEPTOR LIGANDS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES SAS (FR) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299073-A1 | Imidazolyl derivatives | SSTR5, SSTR3, SSTR2 | PTGS2 2698/4885KDM4E 3035/4885HTR2A 245/4885 |
| US-20040176379-A1 | Imidazolyl derivatives | SSTR5, SSTR3, SSTR2 | PTGS2 2621/4885KDM4E 3168/4885HTR2A 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.